Use of a number of laquinimod, which serves to prepare a Medicine to treat a patient Human afflicted with Multiple Sclerosis or presents a clinically isolated Syndrome； a package, a number of laquinimod and a Pharmaceutical composition thereof.
This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with glatiramer acetate. This invention also provides a package and a pharmaceutical composition comprising laquinimod and glatiramer acetate for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with glatiramer acetate in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and glatiramer acetate in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.USO DE UNA CANTIDAD DE LAQUINIMOD, QUE SIRVE PARA PREPARAR UN MEDICAMENTO PARA TRATAR UN PACIENTE HUMANO AFECTADO CON ESCLEROSIS MÚLTIPLE O QUE PRESENTA UN SÍNDROME CLÍNICAMENTE AISLADO； UN PAQUETE, UNA CANTIDAD DE LAQUINIMOD Y UNA COMPOSICIÓN FARMACÉUTICA DEL MISMO.
